(Q46235194)
Statements
An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer (English)
B Parente
R Sotto-Mayor
E Teixeira
T Almodôvar
F Barata
H Queiroga
C Pereira
H Pereira
F Negreiro